Literature DB >> 20174759

An International Sensitivity Index (ISI) derived from patients with abnormal liver function improves agreement between INRs determined with different reagents.

Anne M Sermon1, Julie M Smith, Rhona Maclean, Steve Kitchen.   

Abstract

The International Normalised Ratio (INR)/International Sensitivity Index (ISI) system was developed as a way to standardise the prothrombin time during the monitoring of patients undergoing oral anti-coagulant therapy with vitamin K antagonists. The wide acceptance of the INR has led to its use as one of three parameters used in the Model for End stage Liver disease (MELD) scoring system to aid the prioritisation of patients for liver transplant. Literature published recently has highlighted the potential inadequacy of the INR system in this context. Our aim was to investigate the degree of difference between INR values calculated using an ISI derived from warfarinised patients and those calculated using an ISI derived from patients with liver disease. Prothrombin times from 60 patients with liver disease were determined using three working thromboplastin reagents; Innovin, Thromborel S and Thromboplastin C and two reference thromboplastins; rTF/95 and RBT/05. All thromboplastin reagents tested had standard international sensitivity indices (ISIs) assigned following calibration with patients on oral anticoagulant therapy (ISIvka). As a result of the new calibration each of the working thromboplastin reagents was assigned a specific "liver patient" ISI. Two INR values were calculated for each thromboplastin patient involved in the calibration. A comparison of the mean INRliver with INRvka showed a statistically significant difference between the two values (p<0.0001). A similar relationship existed for INRs on a further 20 patients with liver disease whose plasmas were not used to derive the ISIliver. This difference led to a change in the final MELD score and could therefore affect the prioritisation and management of these patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20174759     DOI: 10.1160/TH09-08-0535

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  3 in total

1.  The validity of the INR system for patients with liver disease.

Authors:  Armando Tripodi
Journal:  J Thromb Thrombolysis       Date:  2011-02       Impact factor: 2.300

2.  A novel non-invasive index using AFP and APTT is associated with liver fibrosis in patients with chronic hepatitis B infection: a retrospective cohort study.

Authors:  Limin Feng; Ke Sun; Jie Zhang; Guofang Feng; Ying Zhao
Journal:  BMJ Open       Date:  2015-09-21       Impact factor: 2.692

3.  Cholesterol esterification in plasma as a biomarker for liver function and prediction of mortality.

Authors:  Thorsten Kaiser; Benedict Kinny-Köster; Michael Bartels; Thomas Berg; Markus Scholz; Cornelius Engelmann; Daniel Seehofer; Susen Becker; Uta Ceglarek; Joachim Thiery
Journal:  BMC Gastroenterol       Date:  2017-04-20       Impact factor: 3.067

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.